AR061728A1 - Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1 - Google Patents

Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1

Info

Publication number
AR061728A1
AR061728A1 ARP070102894A ARP070102894A AR061728A1 AR 061728 A1 AR061728 A1 AR 061728A1 AR P070102894 A ARP070102894 A AR P070102894A AR P070102894 A ARP070102894 A AR P070102894A AR 061728 A1 AR061728 A1 AR 061728A1
Authority
AR
Argentina
Prior art keywords
delta
composition
alpha
ligand
alfa
Prior art date
Application number
ARP070102894A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR061728A1 publication Critical patent/AR061728A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion para tratar un trastorno o afeccion usando un ligando alfa-2-delta, como por ejemplo, ácido (3S,4R,5R)-3-amino-4,5-dimetil octanoico, con gran afinidad y selectividad para el subtipo de la subunidad alfa-2-delta-1del canal de calcio. La administracion del ligando selectivo alfa-2-delta-1, o una sal farmacéuticamente aceptable, a un mamífero, incluyendo un hombre, evita o reduce los efectos adversos en comparacion con la administracion de un ligando no selectivo alfa-2-delta. Reivindicacion 7: La composicion de acuerdo con la reivindicacion 1 caracterizada porque el trastorno o afeccion es seleccionado de dolor, fibromialgia, epilepsia, síndrome de piernas inquietas, sofocos, trastornos del humor y trastornos del sueno.
ARP070102894A 2006-06-30 2007-06-28 Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1 AR061728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81815406P 2006-06-30 2006-06-30

Publications (1)

Publication Number Publication Date
AR061728A1 true AR061728A1 (es) 2008-09-17

Family

ID=38739992

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102894A AR061728A1 (es) 2006-06-30 2007-06-28 Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1

Country Status (4)

Country Link
JP (1) JP2008013555A (es)
AR (1) AR061728A1 (es)
TW (1) TW200819123A (es)
WO (1) WO2008004067A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0817173A2 (pt) 2007-11-05 2015-12-01 Unilever Nv processo e folha de chá capaz de ser obtida pelo processo
CN110945014A (zh) * 2017-05-26 2020-03-31 诺瓦色生物公司 电压门控钙通道缺陷亚基α2δ及其应用
WO2021079887A1 (ja) * 2019-10-25 2021-04-29 国立大学法人京都大学 タウオパチーの予防又は治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20094817B (en) * 1997-10-27 2009-11-10 Warner Lambert Co Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
NZ503963A (en) * 1997-12-16 2002-09-27 Warner Lambert Co 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders
CZ301608B6 (cs) * 1999-06-10 2010-04-28 Warner-Lambert Company Derivát 3-propyl gamma-aminomáselné kyseliny a farmaceutický prostredek s jeho obsahem
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
CA2444053C (en) * 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
KR100768974B1 (ko) * 2003-09-25 2007-10-22 워너-램버트 캄파니 엘엘씨 알파2델타-단백질에 대한 친화성을 갖는 아미노산
WO2005102390A2 (en) * 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
WO2006017293A2 (en) * 2004-07-13 2006-02-16 Regents Of The University Of California Models and methods for nociception, pain transduction, and screening for analgesic compounds
WO2006100606A2 (en) * 2005-03-24 2006-09-28 Warner-Lambert Company Llc Preparation of beta-amino acid precursors via indium (iii) mediated markovnikov addition and knoevenagel condensation

Also Published As

Publication number Publication date
WO2008004067A2 (en) 2008-01-10
TW200819123A (en) 2008-05-01
WO2008004067A3 (en) 2009-01-29
JP2008013555A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
EA201100896A1 (ru) Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение
UY30686A1 (es) "receptor nicotinico de acetilcolina, subtipo selectivo de amidas de diazabiciloalcanos"
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
MX339555B (es) Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento.
MX2009010450A (es) El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
RU2015109566A (ru) НОВЫЕ ЭКСТРАКТЫ ИЗ CYNARA SCOLYMUS, COFFEA spp. И OLEA EUROPAEA ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
AR061728A1 (es) Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
IL307992A (en) Parasitic formulations containing isoxazoline and methods for treating blepharitis
MX2021007142A (es) Compuestos organicos.
CO6400019A1 (es) Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion
BR112015012497A2 (pt) combinações farmacêuticas
RU2010129409A (ru) Способ лечения псороптоза кроликов и отодектоза плотоядных животных
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno

Legal Events

Date Code Title Description
FA Abandonment or withdrawal